PBIRG Fall Biotech Workshop: Forecasting Research for New Products
Nov 8, 2012 | Philadelphia
ZS forecasting experts Judith Kulich, Managing Principal, Sales Forecasting, and Vaneet Sethi, Principal, will weigh in on the best approaches for new product forecasting at PBIRG’s full day roundtable session. The session is complimentary to PBIRG members and pharma/biotech company attendees.
Forecasting Research for New Products
There are striking differences in the new product forecasting methodologies companies use. There are also differences in how companies adjust from research stated (preference) share to actual (demand) share. What is the truth? Can there be several truths depending on forecast specifics? PBIRG's Biotech Workshop is designed to provide answers! Our expert panel have diverse viewpoints on these issues and will clarify advantages and disadvantages.
This workshop will address:
- When and why do you recommend certain forecasting approaches?
- What alternative methodologies do you consider? (e.g., standard conjoint, other conjoint, allocation, patient cases, analogs, monadic profiles, availability and order of entry modeling, simulating uptake curves, other)
- Advantages/disadvantages? (e.g., cost, sample size, standard error)
- When is precision an illusion?
- How does therapeutic area affect your approach?
- How do you incorporate unknown competitive profiles?
- How do you adjust from research stated (preference) to actual (demand) share?
- Examples: Corroborating questions, standard reduction, norms (e.g., likelihood to prescribe), calibration with IMS or Tandem, Pessemier or Logit transformation
- How does market access factor into share estimates?
- What techniques or normative data sets exist to determine whether your prediction of market share is correct?
For more conference information and online registration, please visit the